Novozymes plans to relocate supply chain activities to Denmark
A thorough internal study shows that Novozymes can reduce production costs by moving the SCO-related activities to Denmark. This is due to large-scale advantages and the elimination of double handling and unnecessary transportation of products.
"This step would make a great deal of sense in business terms, but we deeply regret the impact it would have on the employees affected," explains Andrew Fordyce, General Manager. "Novozymes Switzerland AG will continue to have high strategic importance for Novozymes in the future as the company's Swiss subsidiary, with a strong focus on marketing and technical service activities. There are no plans to move areas or activities other than those mentioned."
Novozymes' management will now enter into dialogue with employees to discuss alternative solutions. If no alternative solution is found, the company's management will help handling the transition and prepare the employees affected to search for a new job.
Most read news
Organizations
Other news from the department manufacturing
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.